Clonal T‐cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA‐A*0206

Abstract

Towards the goal of identifying tumor-rejection antigens on eradicated tumors in bone and soft tissue sarcomas, we evaluated the immune response against antigens presented by lost HLA class I molecules. Tumor specimens and peripheral blood samples were obtained from a 70-year-old woman with pleomorphic malignant fibrous histiocytoma. Over 1-year culture, a tumor cell line (MFH2004) was established. A B-cell line infected with Epstein-Barr virus (B2004-EBV) was developed from the blood samples. HLA genotypes of B2004-EBVcells were

High Expression of CD109 Antigen Regulates the Phenotype of Cancer Stem-Like Cells/Cancer-Initiating Cells in the Novel Epithelioid Sarcoma Cell Line ESX and Is Related to Poor Prognosis of Soft Tissue Sarcoma

“…The human synovial sarcoma cell line YaFuSS and FU-EPS-1 were gifts from Dr J. Toguchida (Kyoto University) [9] and Dr H. Iwasaki (Fukuoka University) [10]. The human osteosarcoma cell line OS2000 and KIKU, and the human malignant fibrous histiocytoma cell lines MFH2003 and MFH2004 were established in our laboratory [11-14]. …”

Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas

“…Moreover, it might become possible to identify CTL-defined CSC-specific tumour antigens for immunotherapy targeting CSCs. Thus far, we have been trying to identify CTLdefined tumour antigens by forward and reverse immunological approaches and have carried out antigenic peptide vaccination trials in bone and soft tissue sarcomas (Sato et al, 2002;Ida et al, 2004;Tsukahara et al, 2004Tsukahara et al, , 2008aTsukahara et al, , b, 2009Kawaguchi et al, 2005;Kimura et al, 2008). Currently, we are trying to establish autologous CTL clones recognising SP cells of MFH2003 from tumour-infiltrating lymphocytes.…”